Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 1, 2009, Pages 36-43

  Pradel, Vincent ^a,b,c   Frauger, Elisabeth ^b,c   Thirion, Xavier ^a   Ronfle, Eléonore ^d   Lapierre, Véronique ^d   Masut, Alain ^d   Coudert, Christine ^d   Blin, Olivier ^b,c   Micallef, Joëlle ^b,c  

^a School of Medicine   (France)

^b TIMONE HOSPITAL   (France)

^c CNRS   (France)

^d Medical Local Service   (France)

Author keywords

Buprenorphine; Doctor shopping; Drug utilization study; France; Prescription monitoring program

Indexed keywords

BUPRENORPHINE; NARCOTIC AGENT;

ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOCTOR SHOPPING; DRUG MEGADOSE; DRUG UTILIZATION; FRANCE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH PROGRAM; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREND STUDY; ADDICTION; CLINICAL PRACTICE; DOCTOR PATIENT RELATION; FACTUAL DATABASE; HUMAN; STANDARD; STATISTICS;

BUPRENORPHINE; DATABASES, FACTUAL; FRANCE; HEALTH SERVICES ACCESSIBILITY; HUMANS; NARCOTICS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; SUBSTANCE-RELATED DISORDERS;

EID: 59049094643     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1681     Document Type: Article

References (27)

1. Auriacombe M, Fatseas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict 2004; 13: S17-S28.
2. Cadet-Taïrou A, Costes JM, Bello PY, et al. Quel est le nombre d'usagers d'opiacés sous BHD? [What is the number of opiates users under high dosage buprenorphine ?]. Tendances 2004; 37: 1-2. http://www.ofdt.fr/BDD/publications/docs/eftxack6.pdf (accessed February 25, 2008).
3. Thirion X, Lapierre V, Micallef J, et al. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 2002; 65: 197-204.
4. Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96: 267-272.
5. Modelon H, Frauger E, Laurenceau D, et al. Abus et dépendances aux produits psychoactifs: étude de consommations à travers l'enqueête OPPIDUM 2004 du réseau des CEIP [Psychotropic drug addiction: consumption study of specific population by the survey OPPIDUM 2004 from the CEIP network]. Therapie 2007; 62: 337-346.
6. Bello PY, Toufik A, Gandilhon M, et al., Phénomènes émergents liés aux drogues en 2003-Cinquième rapport national du dispositif TREND [Emerging phenomenon on drugs in 2003-Fifth report of TREND structure]. OFDT, Saint-Denis; 2004. http://www.ofdt.fr/BDD/publications/docs/epfxpbka.pdf (accessed on February 25, 2008).
7. Pradel V, Thirion X, Ronfle E, et al. Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol Drug Saf 2004; 13: 473-481.
8. Martyres RF, Clode D, Burns JM. Seeking drugs or seeking help? Escalating "doctor shopping" by young heroin users before fatal overdose. Med J Aust 2004; 180: 211-214.
9. Bulla R. Diversion investigation units - methods, utilities, and limitations. NIDA Res Monogr 1993; 131: 145-150.
10. Czechowicz D. The impact of prescription drug control systems on medical practice and patient care - a summary of research recommendations. NIDA Res Monogr 1993; 131: 325-329.
11. Horgan C, Prottas J, Tompkins C, et al. Summary and conclusions of a review of prescription drug diversion control methods. NIDA Res Monogr 1993; 131: 206-223.
12. Inciardi JA, Surratt HL, Kurtz SP, et al. Mechanisms of prescription drug diversion among drug-involved club and street-based populations. Pain Med 2007; 8: 171-183.
13. Simoni-Wastila L, Tompkins C. Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential. Subst Use Misuse 2001; 36: 1275-1296.
14. Fumeau B, Malinvaud F, Mattern B, et al. Subutex®: attention aux patients nomades et aux coprescriptions de benzodiazépines! [Subutex®: Be careful to nomadic patients and co-prescriptions of benzodiazepines!. Revue du Praticien - Médecine générale 2000; 517: 2133-2137.
15. Spoerry A, Mezzarobba F, Bonnet P, et al. Suivi sur trois ans d'une population de malades dépendants aux opiacés [Three years follow-up of an opiates addicts population]. Revue médicale de l'Assurance Maladie 2000; 3: 21-27.
16. Damon MN, Claroux-Bellocq D, Degré A. Traitement de substitution par la buprénorphine haut dosage en medecine de ville en Aquitaine [Office based high dosage buprenorphine treatment in Aquitaine]. Revue médicale de l'Assurance Maladie 2001; 32: 311-318.
17. Claroux-Bellocq D, De Bailliencourt S, Saint-Jean F, et al. Les traitements de substitution aux opiacés en France métropolitaine en 2000: les données du régime général de l'assurance maladie [Substitute drug treatment for opiate addiction in metropolitan France in 2000: data from the General Healthcare Fund]. Revue médicale de l'Assurance Maladie 2003; 34: 93-102.
18. Lapeyre-Mestre M, Llau ME, Gony M, et al. Opiate maintenance with buprenorphine in ambulatory care: A 24-week follow-up study of new users. Drug Alcohol Depend 2003; 72: 297-303.
19. Feroni I, Peretti-Watel P, Masut A, et al. French general practitioners' prescribing high-dosage buprenorphine maintenance treatment: is the existing training (good) enough? Addict Behav 2005; 30: 187-191.
20. Frauger E, Thirion X, Chanut C, et al. Détournement d'usage du trihexyphenidyle (Artane, Parkinane): tendances récentes [Misuse of trihexyphenidyl (Artane, Parkinane): recent trends]. Therapie 2003; 58: 541-547.
21. Informations sur le bon usage du SUBUTEX® [Information on good use of SUBUTEX®]. AFSSaPS, Saint Denis; July 2003. http://agmed.sante.gouv.fr/htm/10/filltrpsc/lp030703.htm (accessed on February 25, 2008).
22. Plan d'action concernant les traitements de substitution aux opiacés. [Action plan concerning opiate maintenance treatment]. Assurance Maladie, Paris; 2004. http://www.ameli.fr/fileadmin/ user_upload/documents/trait_substitut_opiaces.pdf (accessed on February 25, 2008).
23. Cadet-Taïrou A, Gandilhon M, Toufik A, et al., Phénomènes émergents liés aux drogues en 2005 - Septième rapport national du dispositif TREND, OFDT, Saint-Denis; January 2007. http://www.ofdt.fr/BDD/publications/docs/ epfxacn1.pdf (accessed on February 25, 2008).
24. Chatot F, Zurbach E. Tendances Récentes et Nouvelles Drogues. Prérapport de site pour l'OFDT. OFDT, Saint Denis; January 2007. http://www.ofdt.fr/ofdt/fr/trend/mars05.pdf (accessed on February 25, 2008).
25. Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol 2004; 150: 1-10.
26. Lo HY, Leong CS. Surgical complications in parenteral Subutex abusers. Singapore Med J 2006; 47: 924-927.
27. Escots S, Fahet G. Usages non substitutifs de la buprénorphine haut-dosage - Investigation menée en France, en 2002-2003 [Non medical use of high dosage buprenorphine - A study in France in 2002-2003] OFDT, Paris; June 2004. http://www.ofdt.fr/BDD/publications/ docs/epfxsek6.pdf (accessed on February 25, 2008).